Supernus

FDA swats away Supernus’ Parkinson’s disease infusion pump for 3rd time
Fierce Pharma
Mon, 04/8/24 - 11:07 am
Medtech
FDA
Supernus
Parkinson's Disease
Potential FDA approval for Supernus’s SPN-830 in Parkinson’s but challenges remain
Clinical Trials Arena
Mon, 10/16/23 - 10:18 am
Supernus
SPN-830
Parkinson's Disease
FDA
Supernus Announces New Qelbree Data Showing Improvement in ADHD Symptoms
Drugs.com
Sun, 09/10/23 - 07:55 pm
Supernus
Qelbree
clinical trials
ADHD
Go or no go? GSK takes its turn with a novel anemia class
EP Vantage
Fri, 09/30/22 - 10:52 am
FDA
GSK
Amicus Therapeutics
AstraZeneca
Novartis
Supernus
JNJ
Ipsen
Y-mAbs Therapeutics
Why Supernus' Acquisition of Adamas Is a Smart Move
Motley Fool
Thu, 10/21/21 - 09:30 am
Supernus
Adamas Pharmaceuticals
M&A
Parkinson's Disease
Supernus expands its portfolio of Parkinson's drugs with a $400M+ buyout
Endpoints
Mon, 10/11/21 - 10:08 am
Supernus
Parkinson's Disease
M&A
Adamas Pharmaceuticals
Novavax taps Sanofi, Supernus vets amid quest to get its COVID-19 vaccine over the FDA finish line
Fierce Pharma
Tue, 08/17/21 - 10:14 am
Novavax
vaccines
COVID-19
Sanofi
Supernus
First-quarter catalysts for the smaller players
EP Vantage
Fri, 12/18/20 - 10:54 am
FDA
Supernus
Wave Life Sciences
Rhythm
Calithera
Matinas
Regenexbio
FDA hits Supernus with double whammy, handing biotech a CRL and RTF on same day
Endpoints
Tue, 11/10/20 - 10:40 am
Supernus
FDA
SPN-812
ADHD
SPN-830
Parkinson's Disease
Tardy marketing application filing, trial failure troubles Supernus investors
Endpoints
Wed, 11/6/19 - 10:23 am
Supernus
earnings
ADHD
SPN-812
SPN-810
clinical trials
Supernus struggles to gain attention
EP Vantage
Fri, 03/29/19 - 10:23 am
Supernus
ADHD
SPN-812
clinical trials
Supernus epilepsy drug secures label expansion
Biopharma Dive
Wed, 12/19/18 - 12:30 am
Supernus
Oxtellar XR
epilepsy
partial onset seizures
FDA
Supernus says ADHD drug trounces rivals, but shares slide
Pharmaforum
Fri, 12/7/18 - 10:48 am
Supernus
ADHD
SPN-812
clinical trials
Supernus adds epilepsy candidate with $185M Biscayne buy
Fierce Biotech
Sun, 09/16/18 - 02:24 pm
Supernus
M&A
Biscayne Neurotherapeutics
epilepsy
FDA issues warning to Supernus for 'misleading' marketing
BioPharma Dive
Wed, 11/16/16 - 09:50 pm
FDA
Supernus
Oxtellar XR
epilepsy
Supernus Receives FDA Fast Track Designation for SPN-810
Marketwatch
Sat, 08/16/14 - 04:29 pm
Supernus
FDA
fast track
SPN-810
ADHD